A Commentary on “Magnetic Resonance Spectroscopy Lipids Peak May Serve as a Potential Biomarker for Back Pain in Intervertebral Disc Degeneration: An Integrative Metabolomics and Proteomics Study Investigating the Role of the Lipid Droplets-Interleukin-17 Inflammatory Axis”
Article information
Low back pain (LBP) remains one of the leading causes of disability worldwide, yet its biological underpinnings, particularly in discogenic pain, are still incompletely understood. While conventional imaging has traditionally focused on structural degeneration, increasing evidence suggests that metabolic and inflammatory processes within the intervertebral disc play a pivotal role in symptom generation [1]. In this context, the study by Chen et al. [2] provides compelling evidence that magnetic resonance spectroscopy (MRS)-detected lipid peaks may represent a clinically meaningful biomarker linking altered disc metabolism to inflammation-driven discogenic pain.
A key strength of this work lies in its integrative, multimodal design. By combining in vivo MRS with lipidomics, proteomics, histology, and patient-reported outcome measures, the authors move beyond purely morphological assessment toward a biologically informed characterization of intervertebral disc degeneration (IDD). Patients exhibiting a predominant lipid peak on MRS showed significantly higher pain intensity and disability scores compared with those without this spectral feature. Importantly, these imaging findings were biologically substantiated by the demonstration of lipid droplet accumulation in nucleus pulposus (NP) cells and concomitant activation of the interleukin (IL)-17 inflammatory pathway.
These results are consistent with recent observations in the field. Tu et al. [3] reported an increased lipid peak on MRS in disc specimens obtained from patients with advanced IDD, alongside lipid droplet accumulation and elevated triglyceride content in NP cells. Furthermore, palmitic acid accumulation was shown to induce endoplasmic reticulum stress, mitochondrial dysfunction, lipid droplet deposition, and NP cell senescence. In contrast, phosphatidylcholine, whose levels were reduced in advanced IDD, exerted protective effects, mitigating these pathological processes both in vitro and in vivo. By linking disc cell lipotoxicity to a distinct immune signature and associated pain trajectories, the present study advances the understanding of discogenic LBP and its underlying molecular phenotypes.
The identification of lipid droplet accumulation as a hallmark of painful discs is particularly noteworthy. Once regarded as inert energy reservoirs, lipid droplets are now recognized as dynamic organelles involved in inflammatory regulation and cellular stress responses [4]. Their association with IL-17 signaling, as shown in this study, aligns with emerging evidence implicating IL-17 in IDD and chronic pain [5]. The finding that both IL-17–positive cell proportion and intracellular triglyceride content independently predict pain severity supports the concept that metabolic inflammation, or lipoinflammation, is a central mechanism in discogenic pain. This expands the classical mechanical paradigm of IDD to include immunometabolic dysfunction as a key driver of symptoms [6].
From a clinical perspective, the use of MRS as a noninvasive biomarker is particularly appealing. MRS can be integrated into routine magnetic resonance imaging (MRI) protocols without additional procedural risk, offering a unique opportunity to capture real-time metabolic alterations within the disc [7]. The ability to stratify patients based on metabolic-inflammatory signatures could have significant implications for personalized spine care, including patient selection for anti-inflammatory, biologic, or regenerative therapies. Previous studies have already demonstrated that MRS has a greater accuracy in identifying painful discs compared to discography (while being noninvasive) and predicted a higher treatment success when MRS-positive discs were treated surgically [8,9]. Moreover, MRS-derived lipid peaks may serve as valuable surrogate endpoints in clinical trials, enabling objective monitoring of disease activity and therapeutic response. Integration of MRS data with other quantitative MRI techniques, clinical variables, and multiomics profiles may further support the development of decision-support algorithms for personalized management of discogenic LBP. Ultimately, translating these advances into routine clinical workflows will require multicenter validation, standardized acquisition protocols, and demonstration of cost-effectiveness, but this study provides a compelling foundation for redefining discogenic pain assessment through biologically informed, noninvasive imaging.
Several limitations should nonetheless be acknowledged. The single-center design may limit generalizability, and the cross-sectional nature of the analysis precludes definitive conclusions regarding causality between lipid accumulation, inflammatory activation, and pain progression. Longitudinal studies are needed to determine whether MRS lipid peaks can predict clinical outcomes over time or response to targeted interventions. Additionally, the specificity of this metabolic signature remains to be clarified, as similar lipid-related inflammatory processes may be present in other spinal or musculoskeletal pain conditions.
Nevertheless, this study contributes to a broader paradigm shift in spine research, emphasizing the intervertebral disc as a metabolically active and immunologically responsive organ rather than a passive structural element. By integrating advanced imaging with multiomics technologies, the authors provide a framework for precision diagnostics that may extend beyond discogenic LBP to other degenerative spinal disorders. In summary, MRS-detected lipid peaks appear to reflect underlying immunometabolic alterations closely associated with pain and disability, positioning this technique as a promising noninvasive biomarker with substantial translational potential in the management of IDD.
Notes
Conflict of Interest
The authors have nothing to disclose.